$THRX reports Q4 & FY22 Financials, Shows Progress in Clinical Pipeline
Mar 9th 2023, 12:00 pm
Analyst Summary: Theseus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported their financial results for Q4 and FY 2022, showcasing significant progress across their growing pipeline. Theseus provided updates on two of their clinical candidates, THE-630 and THE-349, with potential clinical readouts for THE- 630 and an IND filing for THE-349 anticipated in 2023. Theseus reported cash, cash equivalents, and marketable securities of $211.2 million as of December 31,2021, enough to fund operations and capital expenditures into the third quarter of 2025. The company incurred $50.1 million in expenses in Q4 2021, along with $135.9 million in expenses for the year. Moreover, the company made forward-looking statements regarding its third development program for BCR-ABL, intending to nominate a development candidate by early 2024. The company disclaims its obligation to update any forward-looking statements unless obligated by law.